On January 7, 2026, Arrowhead Pharmaceuticals, Inc. announced an agreement to sell 3,100,776 shares of common stock at $64.50 per share, and $625 million in convertible senior notes due 2032, aiming for net proceeds of approximately $216.6 million and $681.3 million respectively. The offerings are expected to close on January 9 and January 12, 2026, respectively.